Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026Business Wire • 07/17/26
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic PivotZacks Investment Research • 07/14/26
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer TranscriptSeeking Alpha • 07/13/26
Agenus shares surge as company secures up to $340M to advance colon cancer trialProactive Investors • 07/13/26
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon CancerBusiness Wire • 07/13/26
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026Business Wire • 07/06/26
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026Business Wire • 06/25/26
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?Zacks Investment Research • 05/28/26
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRCBusiness Wire • 05/21/26
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026Business Wire • 05/21/26
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver CancerBusiness Wire • 05/15/26